Commerce Bank bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 281,297 shares of the biopharmaceutical company

Evolve Private Wealth LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 20,202 shares of the biopharmaceutical company

Bank of Nova Scotia purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 791,956 shares of the biopharmaceutical company

Shelter Mutual Insurance Co bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 32,110 shares of the biopharmaceutical compa

Advisors Capital Management LLC compró una nueva posición en Gilead Sciences, Inc. (NASDAQ:GILD - Informe gratuito) durante el segundo trimestre, según la compañía en su presentación más reciente ante la Comisión de Bolsa y Valores. La firma compró 31.697 acciones de la biofarmacéutica

Korea Investment CORP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,003,135 shares of the biopharmaceutical company

Sumitomo Life Insurance Co. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,313 shares of the biopharmaceutical company

Expressive Wealth LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 6,869 shares of the biopharmaceutical company

Westpac Banking Corp acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 78,465 shares of the biopharmaceutical company

Callan Family Office LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 101,450 shares of the biopharmaceutical comp

EP Wealth Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 113,192 shares of the biopharmaceutical company

El director de Gilead Sciences, Inc. (NASDAQ:GILD - Obtenga informe gratuito) Jeffrey Bluestone vendió 5.000 acciones de Gilead Sciences en una transacción fechada el jueves 20 de agosto. Las acciones fueron vendidas a un precio promedio de $145,02, para un valor total de $725.100,00. Tras la venta, el director poseía directamente 10.066 acciones de la empresa, valoradas en 1.459.771,32 dólares. La operación supuso una disminución del 33,19% en su propiedad de las acciones. La venta se reveló en una presentación ante la SEC, a la que se puede acceder a través del sitio web de la SEC. La transacción se ejecutó según un plan comercial preestablecido de la Regla 10b5-1.

PCM Encore LLC compró una nueva posición en Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) en el segundo trimestre, según su divulgación más reciente ante la SEC. La firma compró 7.399 acciones de la biofarmacéutica

Vise Technologies Inc. adquirió una nueva posición en Gilead Sciences, Inc. (NASDAQ:GILD - Informe gratuito) durante el segundo trimestre, según su presentación más reciente ante la Comisión de Bolsa y Valores (SEC). El inversor institucional compró 120.100 acciones de la biofarmacéutica

OVERSEA CHINESE BANKING Corp Ltd compró una nueva posición en acciones de Gilead Sciences, Inc. (NASDAQ:GILD - Informe gratuito) durante el segundo trimestre, según la compañía en su presentación más reciente del Formulario 13F ante la Comisión de Bolsa y Valores (SEC). El fondo compró 14.265 acciones del

Trillium Asset Management LLC compró una nueva posición en acciones de Gilead Sciences, Inc. (NASDAQ:GILD - Informe gratuito) durante el segundo trimestre, según la compañía en su presentación más reciente del Formulario 13F ante la Comisión de Bolsa y Valores. El inversor institucional compró 75.118 acciones

Allworth Financial LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 47,192 shares of the biopharmaceutical company

Altman Advisors Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,931 shares of the biopharmaceutical company